Back to Journals » Pharmacogenomics and Personalized Medicine » Call For Papers

Pharmacogenomics and Personalized Medicine

ISSN: 1178-7066

The following Article Collection/ Thematic Series is currently open for submissions:

Breaking Down the Intricacies of Catabolic Enzymes

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection entitled “Breaking Down the Intricacies of Catabolic Enzymes”, organized by Editor-in-Chief Dr. Martin Bluth in Pharmacogenomics and Personalized Medicine.

Genetic polymorphisms are one way in which people vary from one another. While initial thoughts of "variance" might include a person’s physical features, it is well established that the body’s internal processes are also subject to differ dependent on a multitude of factors. This could include traits that follow them from birth, but also polypharmacy, or even diet.

In line with the advances in modern medicine and genetic testing, research has started to explore the plethora of information linked to catabolic enzyme polymorphisms. This can involve specifying polymorphisms of interest, such as the Cytochrome P450 (CYP) family such as those including the location on the chromosome, possible allelic variations and the impact of these polymorphisms on their parent compound, metabolites or other molecules.

Genetic polymorphisms affect many parts of human function, irrespective of specific health status. This stresses the importance of such polymorphisms further, for both promoting wellbeing in times of health, but to also understand how to approach certain illnesses given the variance in each individual case. This Collection aims to explore the role of catabolic enzyme polymorphisms for a wide variety of disease areas, such as oncology, pulmonology, immunology, psychology, cardiology and more.

The advances in medicine can also leave researchers asking more questions. As more drug compounds reach regulators and medicine agencies, should we be considering how enzyme polymorphisms influence the efficacy and reaction of new medicines? What dangers exist when you inhibit or enhance an enzyme reaction? When considering these possibilities for new medicines, it is also imperative to acknowledge the range of possible reactions and their severity, given that polymorphisms highlight how differences between people should not be underestimated. In turn it is hoped that this Article Collection can promote best practices when prescribing treatments, by placing leading research in this collection.

It is also hoped that research can investigate catabolic enzyme polymorphisms with a wider lens, to understand global trends in such polymorphisms and our understanding of variance on a larger scale. Thus, exploring upcoming topics of interest in this field, such as genomic testing and the use of bioinformatics in predictive technologies, elucidating the intricacies of such interaction are now within reach. These possibilities may provide more control to the individual, their medical practitioners, drug manufacturers by acknowledging human variance stretches beyond what meets the eye. These investigations, questions and early research outcomes highlight the importance of this topic for sustaining our health as a population.

The journal is seeking original submissions and review articles from all disease areas on the following topics related to catabolic enzyme polymorphisms:

• Identifying and understanding polymorphisms (e.g., single-nucleotide polymorphisms)
o All aspects of enzyme metabolism (e.g., catabolism, anabolism)
o Associated mutations, location and allelic compositions
o Functions of interest (e.g., CYPs, steroidogenic enzymes)
• Incidence and variance of poor metabolizers
• Biochemical impact of polymorphisms (e.g., on parent compound, metabolites)
• Impact of polymorphisms on drug reaction symptoms, severity and consequences
o Variance in pro-drug and active drug reactions
• Non-drug consumables (i.e. diet, infectious diseases) and polymorphisms
• How epigenetic and infectious processes affect polymorphism function
• Treatment efficacy and polymorphisms
o Role of polypharmacy on reactions
o Personalized dosages, drug classes and emergency medical care
• Global trends and variation in polymorphisms
• Progress in polymorphism genomic testing and associated benefits and costs
• Use of bioinformatics and modelling systems for predictive testing

All manuscripts submitted to this Article Collection are subject to desk assessment and peer review processes as part of our standard editorial process. We kindly ask all submitting authors to review the Aims and Scope of the journal, alongside the Author Information prior to completing your submission.

The deadline for submissions is 28 February 2024.

Please submit your manuscript on our website, quoting the promo code FEFSM to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Call For Papers

Editor-in-Chief: Dr Martin H Bluth

To see where Pharmacogenomics and Personalized Medicine is indexed online view the Journal Metrics.

What is the advantage to you of publishing in Pharmacogenomics and Personalized Medicine?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although Pharmacogenomics and Personalized Medicine receives many papers, unlike most traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Pharmacogenomics and Personalized Medicine has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
Pharmacogenomics and Personalized Medicine is indexed on PubMed Central (title abbreviation: Pharmgenomics Pers Med). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Dr Martin H. Bluth
Pharmacogenomics and Personalized Medicine

Email: Editor-in-Chief